MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/20451253261463652

Медицинская библиотека · Therapeutic advances in psychopharmacology · 2026

Real-world clinical practice, effectiveness and safety of esketamine nasal spray in major depressive disorder patients: a French prospective cohort (ELLIPSE study).

Llorca Pierre-Michel, Sauvaget Anne, Olié Emilie, Mékaoui Lila, Samalin Ludovic, Rothärmel Maud, Boitez Anne-Laure, Dupin Julien, Wicart Clotilde, Gaudre-Wattinne Emeline, Lacour Hugo, Grenier Benjamin, Astruc Bernard, Falissard Bruno, de Maricourt Pierre

СтатьяОбзорПеревод в очереди

Аннотация

BACKGROUND

Major depressive disorder (MDD) is highly prevalent and associated with significant disability and mortality. Treatment-resistant depression (TRD), defined as inadequate response to ⩾2 antidepressant lines, remains a major therapeutic challenge. Esketamine nasal spray, approved in 2019 for TRD, demonstrated efficacy and safety in randomized trials, but real-world evidence remains limited.

OBJECTIVES

The ELLIPSE study aimed to describe patient characteristics, treatment patterns, and 12-month outcomes of esketamine in routine clinical practice in France.

DESIGN

ELLIPSE was a prospective, multicenter, observational cohort study including adults with unipolar MDD initiating esketamine between Dec 2021 and Jul 2023, followed for 12 months.

METHODS

Data were collected via standardized clinical assessments. Effectiveness was evaluated using the Montgomery-Åsberg Depression Rating Scale (MADRS). Response was defined as ⩾50% MADRS reduction; remission as MADRS ⩽ 10.

RESULTS

A total of 200 patients (mean age 46.6 years; 56.5% female) were enrolled; 97.5% met TRD criteria. Median esketamine exposure was 4.5 months. Mean MADRS decreased from 31.9 at baseline to 12.4 at month 12 (mean change -17.9; 95% CI: -21.6 to -14.2). Response and remission rates reached a plateau at month 2, where the response rate was 55.2% and the remission rate was 33.6%, maintained up to month 12. Adverse events (AEs) occurred in 65.7% of patients, most commonly dissociative states (28.0%) and transient blood pressure increases (11.6%).

CONCLUSION

This real-world study in patients with treatment-resistant depression, including those with comorbidities/prior suicide attempts, showed clinically relevant improvement from month 2, sustained through 12 months. Dissociative symptoms were the most frequent treatment-related AE.

Для цитирования: Llorca Pierre-Michel, Sauvaget Anne, Olié Emilie, Mékaoui Lila, Samalin Ludovic, Rothärmel Maud, Boitez Anne-Laure, Dupin Julien, Wicart Clotilde, Gaudre-Wattinne Emeline, Lacour Hugo, Grenier Benjamin, Astruc Bernard, Falissard Bruno, de Maricourt Pierre. Real-world clinical practice, effectiveness and safety of esketamine nasal spray in major depressive disorder patients: a French prospective cohort (ELLIPSE study).. Therapeutic advances in psychopharmacology. 2026. DOI: 10.1177/20451253261463652.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.